Acetazolamide sodium, 碳酸酐酶 IV 抑制剂

小分子

乙酰唑酰胺钠

Acetazolamide sodium | ACETAZOLAMIDE SODIUM [VANDF] | ACETAMIDE, N-(5-SULFAMOYL-1,3,4-THIADIAZOL-2-YL)-, MONOSODIUM SALT | Acetazolamide sodium [JAN] | N-(5-(Aminosulfonyl)-1,3,4-thiadiazol-2-yl)acetamide Monosodium | Vetamox Soluble Powder | CHEBI:31163

Acetazolamide sodium

A648531-5g

5g

≥99%

2-8°C储存,干燥

冰袋运输

Acetazolamide sodium is a carbonic anhydrase ( CA ) IX inhibitor with an IC 50 of 30 nM for hCA IX . Acetazolamide sodium has diuretic, antihypertensive and anti-gonococcal activities. In Vitro Acetazolamide also inhibits hCA II with an IC 50 of 130 nM. Acetazolamide (Ace) is a small heteroaromatic sulfonamide that binds to various carbonic anhydrases with high affinity, acting as a carbonic anhydrase (CA) inhibitor. Compared with the control group, the high Acetazolamide concentration (AceH, 50 nM), Cisplatin (Cis; 1 µg/mL) and Cis combined with the low Acetazolamide concentration (AceL, 10 nM) treatments significantly reduces viability of Hep-2 cells. Treatment with the Acetazolamide/Cis combination significantly increases the expression levels of P53, as both AceL+Cis and AceH+Cis treatments result in significantly increased P53 protein expression levels compared with the control group. The Ace/Cis combination treatment significantly reduces the bcl-2/bax expression ratio, and increases the expression of caspase-3 protein, compared with the control group. AceL, AceH, Cis and AceL+Cis treatments significantly reduce the bcl-2/bax ratio compared with the control group. Combined Ace and Cis treatment effectively promotes apoptosis in Hep-2 cells. Combined treatment with Ace/Cis markedly decreases the expression of AQP1 mRNA in Hep-2 cells. Both AceH and AceL+Cis treatments decrease the expression of aquaporin-1 (AQP1) mRNA in Hep-2 cells compared with the control group. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo Acetazolamide (40 mg/kg) significantly potentiates the inhibitory effect of MS-275 on tumorigenesis in neuroblastoma (NB) SH-SY5Y xenografts. Acetazolamide (40 mg/kg) and/or MS-275 treatment reduce expression of HIF1-α and CAIX in NB SH-SY5Y xenograft. Acetazolamide (40 mg/kg), MS-275 and Acetazolamide+MS-275 reduce expression of mitotic and proliferative markers in NB SH-SY5Y xenografts.\nAcetazolamide (50 mg/kg; PO, for 3 days) significantly reduces the gonococcal load in the vagina of infected mice by 90% . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid IC50& Target:IC 50 : 30 nM (hCA IX), 130 nM (hCA II)

乙酰唑胺钠是一种碳酸酐酶（CA）IX 抑制剂，对 hCA IX 的 IC 50 为 30 nM。乙酰唑胺钠具有利尿、抗高血压和抗淋球菌活性。

1424-27-7

C4H6N4NaO3S2

245.24 g/mol

13290219

CC(=O)NC1=NN=C(S1)S(=O)(=O)[NH-].[Na+]

sodium;(5-acetamido-1,3,4-thiadiazol-2-yl)sulfonylazanide

1S/C4H6N4O3S2.Na/c1-2(9)6-3-7-8-4(12-3)13(5,10)11;/h1H3,(H3,5,6,7,9,10,11);/q;+1/p-1

MRSXAJAOWWFZJJ-UHFFFAOYSA-M

CC(=O)NC1=NN=C(S1)S(=O)(=O)[NH-].[Na+]

13290219

DMSO : 100 mg/mL (407.76 mM; Need ultrasonic)

2

7

2

243.97 Da

243.97 Da

127.000 Ų

14

0

302

0

2

抑制剂

碳酸酐酶 IV 抑制剂